CMG901 Shows Potential in CLDN18.2-Positive Advanced Gastric/GEJ Cancer

News
Article

CMG901 demonstrated a well-tolerated safety profile in patients with CLDN18.2-positive, advanced gastric/gastroesophageal junction cancer.

 “The data presented today provide a strong rationale to further explore CMG901 as an [antibody-drug conjugate] in CLDN18.2-expressing gastric/GEJ cancer,” according to Rui-Hua Xu, MD, PhD.

“The data presented today provide a strong rationale to further explore CMG901 as an [antibody-drug conjugate] in CLDN18.2-expressing gastric/GEJ cancer,” according to Rui-Hua Xu, MD, PhD.

Investigators reported that treatment with CMG901 resulted in positive clinical efficacy in a population diagnosed with CLDN18.2-positive, advanced gastric/gastroesophageal junction (GEJ) cancer, according to findings from the phase 1 KYM901 (NCT04805307) study.

In a presentation that was given during an American Society of Clinical Oncology (ASCO) Plenary Session, presenting author Rui-Hua Xu, MD, PhD, reported a confirmed overall response rate (ORR) of 42.0% (95% CI, 24.5%-60.9%) at the 2.2 mg/kg dose level (n = 31), 24.0% (95% CI, 12.1%-39.5%) at the 2.6 mg/kg dose level (n = 42), and 38.0% (95% CI, 15.2%-64.6%) at the 3.0 mg/kg dose level (n = 16). Additionally, the confirmed disease control rate (DCR) in each respective arm was 71.0% (95% CI, 52.0%-85.8%), 67.0% (95% CI, 50.5%-80.4%), and 75.0% (95% CI, 47.6%-92.7%).

Xu is a gastrointestinal medical oncologist, professor of the Department of Medical Oncology, and president of Sun Yat-Sen University Cancer Center, Guangzhou, China.

The confirmed ORR in the total patient population was 33.0% (95%, 23.0-43.3%), and the DCR was 70.0% (95% CI, 59.0%-79.0%). Investigators also reported that 2 additional patients had an ongoing, unconfirmed partial response at the study’s data cutoff of July 24, 2023. Additionally, 1 patient of 19 with CLDN18.2-expressing tumors who didn’t meet the immunohistochemistry threshold of 2+/3+ achieved a confirmed partial response.

In an ORR subgroup analysis, Xu indicated the ORR was consistent across patient subgroups, including those with a poor prognosis such as patients with an ECOG performance status of 1 or peritoneal metastases. Additionally, response was seen regardless of previous lines of therapy, with patients who received 3 or more previous lines of therapy deriving benefit. Responses were also seen regardless of previous taxane or anti–PD-1 agent exposure.

“The data presented today provide a strong rationale to further explore CMG901 as an [antibody-drug conjugate] in CLDN18.2-expressing gastric/GEJ cancer,” Xu said.

To be included on the open-label, multicenter study, patients were required to have a pathologically confirmed advanced solid tumor that was refractory or intolerant to standard treatments. Patients also needed to have an ECOG performance status of 0 or 1. Although CLDN18.2 expression was not required in part A of the study; part B required an expression of 2+ or higher membrane staining intensity in 5% or more of tumor cells.

Part A of the study included several dose levels of KYM901, including 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 1.8 mg/kg, 2.2 mg/kg, 2.6 mg/kg, 3.0 mg/kg, 3.4 mg/kg, as well as 2.2 mg/kg, 2.6 mg/kg, and 3.0 mg/kg in part B. The study’s primary end points were adverse effects (AEs) and dose-limiting toxicities in part A, and ORR and recommended phase 2 dose in part B.

A total of 113 patients with gastric/GEJ cancer were included in the study who were treated at the 2.2 mg/kg to 3.0 mg/kg dose levels.

Approximately half of all patients were male (52%), and all patients were Asian (100%). Most had an ECOG performance status of 1 (84%), gastric cancer (90%), and a CLDN18.2 expression of 2+ or more membrane staining in 20% or more tumor cells (83%).

The median progression-free survival at the 2.2 mg/kg, 2.6 mg/kg, and 3.0 mg/kg dose levels were 4.8 months (95% CI, 3.6-6.0), 3.3 months (95% CI, 2.2-6.1), and 14.5 months (95% CI, 3.0-not reached [NR]). Additionally, the median overall survival (OS) in each respective arm was NR (95% CI, 6.5-NR), 8.5 months (95% CI, 6.2-NR), and NR (95% CI, 5.2-NR). The 9-month OS rate in at the 2.2 mg/kg, 2.6 mg/kg, and 3.0 mg/kg dose levels were 70.7%, 46.9%, and 56.3%, respectively.

The median duration of response (DOR) was 6.3 months (95% CI, 4.2-NR) in the 2.2 mg/kg cohort with a median follow-up of 5.5 months (95% CI, 4.2-9.0), 5.7 months (95% CI, 2.9-NR) in the 2.6 mg/kg cohort at a median follow-up of 6.0 months (95% CI, 3.8-8.1), and 12.6 months (95% CI, 2.4-NR) at a median follow-up of 7.7 months (95% CI, 5.2-9.7). The median DOR in the overall patient population was 7.2 months (95% CI, 5.3-NR) with a median follow-up of 6.0 months (95% CI, 4.2-8.3).

Drug-related treatment-emergent AEs (TEAEs) occurred in all patients, with grade 3 or higher TEAEs reported in 64% of patients, 54% of which were related to treatment. Serious AEs were reported in 47% of patients, 31% of which were related to treatment. A total of 8% of patients discontinued due to TEAEs.

Common any-grade TEAEs in the overall patient population included anemia (63%), vomiting (58%), hypoalbuminemia (58%), and weight decrease (56%). Grade 3 or higher TEAEs included neutrophil count decrease (19%), anemia (13%), and vomiting (10%).

Reference

Xu RH, Ruan DY, Zhang DS, et al. KYM901 (NCT04805307): a phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. Presented at the American Society of Clinical Oncology Plenary Session. November 7, 2023; virtual; abstract 434420.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content